Stock falls 14% after revenue and loss forecasts miss expectations
- Teladoc Health shares slide 14% on 1Q, 2024 outlook
- Stock falls 32% over the last 12 months
- Revenue forecast for first quarter and 2024 falls short of expectations
- Loss per share also below Wall Street’s estimates
- Company expects low- to mid-single-digit annual consolidated revenue growth
Teladoc Health shares dropped 14% in afterhours trading as the company’s outlook for the first quarter and 2024 fell short of Wall Street’s expectations. The stock has also fallen 32% over the last 12 months. Teladoc forecasted revenue between $630 million and $645 million for the first quarter, lower than the expected $673.3 million. The company also projected a loss per share between 45 cents and 55 cents, while analysts estimated a loss of around 41 cents. For 2024, Teladoc guided for revenue between $2.64 billion and $2.74 billion, below the expected $2.77 billion, and a loss per share between 80 cents and $1.10, compared to the estimated $1.20. Additionally, the company issued a three-year outlook with low- to mid-single-digit annual consolidated revenue growth.
Factuality Level: 8
Factuality Justification: The article provides specific details about Teladoc Health’s stock performance, revenue forecasts, and analyst expectations. The information presented is factual and based on verifiable data without any apparent bias or sensationalism.
Noise Level: 2
Noise Justification: The article provides clear and concise information about Teladoc Health’s stock performance and financial outlook. It sticks to the relevant details without unnecessary filler content or repetition. The article supports its claims with specific numbers and comparisons to analysts’ expectations.
Financial Relevance: Yes
Financial Markets Impacted: Teladoc Health
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to the financial performance and outlook of Teladoc Health, a telehealthcare-services provider. It discusses the company’s lower-than-expected revenue and loss per share forecasts for the current quarter and 2024. This information is relevant to financial markets and investors.
Public Companies: Teladoc Health (TDOC)
Key People: Denny Jacob (Author)
Reported publicly:
www.marketwatch.com 
